All components of an intracerebral kallikrein-kinin system have been d
escribed. Thus, bradykinin (BK) acting from the parenchymal site as we
ll as from the blood site may influence cerebral microcirculation. BK
is a potent dilator of extra- and intraparenchymal cerebral arteries w
hen acting from the perivascular site. The vasomotor effect of BK is m
ediated by B-2 receptors which appear to be located at the abluminal m
embrane of the endothelial cell. The effect of BK is mediated by NO, p
rostanoids, free radicals, H2O2 or leukotrienes depending on the anima
l species and on the location of the artery. Selective opening of the
blood-brain barrier for small tracers (Na+-fluorescein; MW, 376) has b
een found in cats during cortical superfusion or intraarterial applica
tion of BK. This leakage is mediated by B-2 receptors located at the l
uminal and abluminal membrane of the endothelial cells. Formation of b
rain edema has been found after ventriculo-cisternal perfusion or inte
rstitial infusion of BK. This can be explained by increase of vascular
permeability and cerebral blood flow due to arterial dilatation thus
enhancing driving forces for the extravasation. An increase of the BK
concentration in the interstitial space of the brain up to concentrati
ons which induce extravasation, dilatation and oedema formation has be
en found under several pathological conditions, Thus, BK may be involv
ed in oedema formation after cold lesion, concussive brain injury, tra
umatic spinal cord and ischemic brain injury. The mediator role of BK
in brain edema is further supported by therapeutic results. Brain swel
ling due to cold lesion or ischemia could be diminished by treatment w
ith kallikrein-inhibitors. Similarly, dilatation of cerebral arteriole
s after concussive brain injury was reduced by blockade of B-2 recepto
rs. Thus, all criteria favour BK as one mediator of vasogenic oedema.